Inhibrx Ret. on equity
What is the Ret. on equity of Inhibrx?
The Ret. on equity of Inhibrx, Inc. is 1,617.60%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Inhibrx
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Companies with ret. on equity similar to Inhibrx
- Champions Oncology Inc has Ret. on equity of 1,481.12%
- HCL Infosystems has Ret. on equity of 1,495.17%
- Ritter Pharmaceuticals has Ret. on equity of 1,499.01%
- ENENSYS Technologies SA has Ret. on equity of 1,543.00%
- Invo Bioscience Inc has Ret. on equity of 1,582.40%
- INVO Bioscience has Ret. on equity of 1,582.40%
- Inhibrx has Ret. on equity of 1,617.60%
- Canuc Resources has Ret. on equity of 1,641.38%
- on Inc has Ret. on equity of 1,658.96%
- Oil Country Tubular has Ret. on equity of 1,676.72%
- A-Labs Capital II has Ret. on equity of 1,681.23%
- Centric Brands has Ret. on equity of 1,705.86%
- Cloud DX has Ret. on equity of 1,762.91%